Can a daily pill keep a rare heart disease in check for the long haul?

This study tests the long-term safety and tolerability of acoramidis, an oral medication that stabilizes the transthyretin protein, in people newly diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that can lead to heart failure. Participants who completed an earlier study of acoramidis may join this extension, where they will continue taking the drug twice daily. Researchers will monitor for side effects and changes in health measures over time to see if the drug remains safe for extended use.